News
Envision this possible future clinical scenario: a breast cancer patient and her physicians are deciding on the best possible ...
LONDON, GREATER LONDON, UNITED KINGDOM, June 5, 2025 /EINPresswire.com/ -- The Business Research Company’s Latest Report Explores Market Driver, Trends, Regional Insights - Market Sizing & Forecasts ...
3don MSN
HER2+ breast cancer usually undergo preoperative therapy with multi-agent chemotherapy in combination with anti-HER2 ...
Envision this possible future clinical scenario: a breast cancer patient and her physicians are deciding on the best possible ...
Vepdegestrant, an investigational estrogen receptor (ER) degrader, known as a proteolysis-targeting chimera (PROTAC ), ...
1d
SurvivorNet on MSNAn Exciting Option For Difficult-To-Treat HER2+ Gastric Cancer: What New Data Means For PatientsFor the first time, a medicine aimed directly at the HER2 protein improved overall survival after gastric cancer progressed ...
Among patients with ESR1-mutant, ER+, HER2– advanced breast cancer, vepdegestrant improved survival without progression when ...
4d
MedPage Today on MSNADC-Pertuzumab Promising as New Standard in HER2-Positive Metastatic Breast CancerAs such, "the combination of T-DXd and pertuzumab may represent a new first-line standard of care for patients with ...
Camizestrant plus CDK4/6 inhibition improved progression-free survival when given to patients with ESR1-mutant ER+/HER2– ...
AI could help pathologists identify HER2-low and HER2-ultralow breast cancers with greater accuracy, according to findings scheduled for presentation at ASCO Annual Meeting.In a study of more than 100 ...
The FDA has accepted and granted priority review to an NDA for sevabertinib in previously treated HER2+ non-small cell lung ...
In an interim analysis from the DESTINY-Breast09 study, the combination of the antibody-drug conjugate trastuzumab deruxtecan ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results